Arsenic Exposure and Type 2 Diabetes: MicroRNAs as Mechanistic Links?

Research output: Research - peer-reviewReview article

  • 2 Citations

Abstract

Purpose of Review: The goal of this review is to delineate the following: (1) the primary means of inorganic arsenic (iAs) exposure for human populations, (2) the adverse public health outcomes associated with chronic iAs exposure, (3) the pathophysiological connection between arsenic and type 2 diabetes (T2D), and (4) the incipient evidence for microRNAs as candidate mechanistic links between iAs exposure and T2D. Recent Findings: Exposure to iAs in animal models has been associated with the dysfunction of several different cell types and tissues, including liver and pancreatic islets. Many microRNAs that have been identified as responsive to iAs exposure under in vitro and/or in vivo conditions have also been shown in independent studies to regulate processes that underlie T2D etiology, such as glucose-stimulated insulin secretion from pancreatic beta cells. Summary: Defects in insulin secretion could be, in part, associated with aberrant microRNA expression and activity. Additional in vivo studies need to be performed with standardized concentrations and durations of arsenic exposure in order to evaluate rigorously microRNAs as molecular drivers of iAs-associated diabetes.

LanguageEnglish (US)
Article number18
JournalCurrent Diabetes Reports
Volume17
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Arsenic
MicroRNAs
Type 2 Diabetes Mellitus
Insulin
Insulin-Secreting Cells
Islets of Langerhans
Animal Models
Public Health
Glucose
Liver
Population
In Vitro Techniques

Keywords

  • Arsenic
  • Diabetes
  • Insulin
  • Metabolism
  • MicroRNAs
  • β-Cell

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Arsenic Exposure and Type 2 Diabetes : MicroRNAs as Mechanistic Links? / Beck, Rowan; Styblo, Miroslav; Sethupathy, Praveen.

In: Current Diabetes Reports, Vol. 17, No. 3, 18, 01.03.2017.

Research output: Research - peer-reviewReview article

@article{682e65beb2f642cd80e94f862e347437,
title = "Arsenic Exposure and Type 2 Diabetes: MicroRNAs as Mechanistic Links?",
abstract = "Purpose of Review: The goal of this review is to delineate the following: (1) the primary means of inorganic arsenic (iAs) exposure for human populations, (2) the adverse public health outcomes associated with chronic iAs exposure, (3) the pathophysiological connection between arsenic and type 2 diabetes (T2D), and (4) the incipient evidence for microRNAs as candidate mechanistic links between iAs exposure and T2D. Recent Findings: Exposure to iAs in animal models has been associated with the dysfunction of several different cell types and tissues, including liver and pancreatic islets. Many microRNAs that have been identified as responsive to iAs exposure under in vitro and/or in vivo conditions have also been shown in independent studies to regulate processes that underlie T2D etiology, such as glucose-stimulated insulin secretion from pancreatic beta cells. Summary: Defects in insulin secretion could be, in part, associated with aberrant microRNA expression and activity. Additional in vivo studies need to be performed with standardized concentrations and durations of arsenic exposure in order to evaluate rigorously microRNAs as molecular drivers of iAs-associated diabetes.",
keywords = "Arsenic, Diabetes, Insulin, Metabolism, MicroRNAs, β-Cell",
author = "Rowan Beck and Miroslav Styblo and Praveen Sethupathy",
year = "2017",
month = "3",
doi = "10.1007/s11892-017-0845-8",
volume = "17",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - Arsenic Exposure and Type 2 Diabetes

T2 - Current Diabetes Reports

AU - Beck,Rowan

AU - Styblo,Miroslav

AU - Sethupathy,Praveen

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Purpose of Review: The goal of this review is to delineate the following: (1) the primary means of inorganic arsenic (iAs) exposure for human populations, (2) the adverse public health outcomes associated with chronic iAs exposure, (3) the pathophysiological connection between arsenic and type 2 diabetes (T2D), and (4) the incipient evidence for microRNAs as candidate mechanistic links between iAs exposure and T2D. Recent Findings: Exposure to iAs in animal models has been associated with the dysfunction of several different cell types and tissues, including liver and pancreatic islets. Many microRNAs that have been identified as responsive to iAs exposure under in vitro and/or in vivo conditions have also been shown in independent studies to regulate processes that underlie T2D etiology, such as glucose-stimulated insulin secretion from pancreatic beta cells. Summary: Defects in insulin secretion could be, in part, associated with aberrant microRNA expression and activity. Additional in vivo studies need to be performed with standardized concentrations and durations of arsenic exposure in order to evaluate rigorously microRNAs as molecular drivers of iAs-associated diabetes.

AB - Purpose of Review: The goal of this review is to delineate the following: (1) the primary means of inorganic arsenic (iAs) exposure for human populations, (2) the adverse public health outcomes associated with chronic iAs exposure, (3) the pathophysiological connection between arsenic and type 2 diabetes (T2D), and (4) the incipient evidence for microRNAs as candidate mechanistic links between iAs exposure and T2D. Recent Findings: Exposure to iAs in animal models has been associated with the dysfunction of several different cell types and tissues, including liver and pancreatic islets. Many microRNAs that have been identified as responsive to iAs exposure under in vitro and/or in vivo conditions have also been shown in independent studies to regulate processes that underlie T2D etiology, such as glucose-stimulated insulin secretion from pancreatic beta cells. Summary: Defects in insulin secretion could be, in part, associated with aberrant microRNA expression and activity. Additional in vivo studies need to be performed with standardized concentrations and durations of arsenic exposure in order to evaluate rigorously microRNAs as molecular drivers of iAs-associated diabetes.

KW - Arsenic

KW - Diabetes

KW - Insulin

KW - Metabolism

KW - MicroRNAs

KW - β-Cell

UR - http://www.scopus.com/inward/record.url?scp=85015005735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015005735&partnerID=8YFLogxK

U2 - 10.1007/s11892-017-0845-8

DO - 10.1007/s11892-017-0845-8

M3 - Review article

VL - 17

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 3

M1 - 18

ER -